117 related articles for article (PubMed ID: 19968573)
1. The missing linkage: what pharmacogenetic associations are left to find in CYP3A?
Perera MA
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):17-28. PubMed ID: 19968573
[TBL] [Abstract][Full Text] [Related]
2. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test.
Oneda B; Crettol S; Jaquenoud Sirot E; Bochud M; Ansermot N; Eap CB
Pharmacogenet Genomics; 2009 Nov; 19(11):877-83. PubMed ID: 19801957
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic study of ABCB1 and CYP3A5 genes during the first year following heart transplantation regarding tacrolimus or cyclosporine levels.
Jordán de Luna C; Herrero Cervera MJ; Sánchez Lázaro I; Almenar Bonet L; Poveda Andrés JL; Aliño Pellicer SF
Transplant Proc; 2011; 43(6):2241-3. PubMed ID: 21839244
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
Zhou SF; Liu JP; Chowbay B
Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
[TBL] [Abstract][Full Text] [Related]
5. CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.
Wang J
Expert Rev Mol Diagn; 2009 May; 9(4):383-90. PubMed ID: 19435458
[TBL] [Abstract][Full Text] [Related]
6. Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?
Kirwan C; MacPhee I; Philips B
Expert Opin Drug Metab Toxicol; 2010 Jun; 6(6):761-71. PubMed ID: 20402562
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
[TBL] [Abstract][Full Text] [Related]
8. Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans.
Kazuki Y; Kobayashi K; Aueviriyavit S; Oshima T; Kuroiwa Y; Tsukazaki Y; Senda N; Kawakami H; Ohtsuki S; Abe S; Takiguchi M; Hoshiya H; Kajitani N; Takehara S; Kubo K; Terasaki T; Chiba K; Tomizuka K; Oshimura M
Hum Mol Genet; 2013 Feb; 22(3):578-92. PubMed ID: 23125282
[TBL] [Abstract][Full Text] [Related]
9. Challenges for drug studies in children: CYP3A phenotyping as example.
de Wildt SN; Ito S; Koren G
Drug Discov Today; 2009 Jan; 14(1-2):6-15. PubMed ID: 18721895
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.
Anglicheau D; Legendre C; Beaune P; Thervet E
Pharmacogenomics; 2007 Jul; 8(7):835-49. PubMed ID: 18240909
[TBL] [Abstract][Full Text] [Related]
11. Genetic factors for individual administration of immunosuppressants in organ transplantation.
Yu SF; Wu LH; Zheng SS
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):337-44. PubMed ID: 16911928
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques.
Uno Y; Matsushita A; Osada N; Uehara S; Kohara S; Nagata R; Fukuzaki K; Utoh M; Murayama N; Yamazaki H
Drug Metab Dispos; 2010 Feb; 38(2):209-14. PubMed ID: 19910514
[TBL] [Abstract][Full Text] [Related]
13. Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.
Yoshida K; Sun B; Zhang L; Zhao P; Abernethy DR; Nolin TD; Rostami-Hodjegan A; Zineh I; Huang SM
Clin Pharmacol Ther; 2016 Jul; 100(1):75-87. PubMed ID: 26800425
[TBL] [Abstract][Full Text] [Related]
14. Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology.
Abe S; Kobayashi K; Oji A; Sakuma T; Kazuki K; Takehara S; Nakamura K; Okada A; Tsukazaki Y; Senda N; Honma K; Yamamoto T; Ikawa M; Chiba K; Oshimura M; Kazuki Y
Sci Rep; 2017 Nov; 7(1):15189. PubMed ID: 29123154
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics.
Johnson AD; Wang D; Sadee W
Pharmacol Ther; 2005 Apr; 106(1):19-38. PubMed ID: 15781120
[TBL] [Abstract][Full Text] [Related]
16. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.
van Waterschoot RA; Schinkel AH
Pharmacol Rev; 2011 Jun; 63(2):390-410. PubMed ID: 21490128
[TBL] [Abstract][Full Text] [Related]
17. Engineering of human CYP3A enzymes by combination of activating polymorphic variants.
Neunzig I; Widjaja M; Drăgan CA; Peters FT; Maurer HH; Bureik M
Appl Biochem Biotechnol; 2012 Oct; 168(4):785-96. PubMed ID: 22899011
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of aldo-keto reductase 1C (AKR1C) enzymes.
Alshogran OY
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1063-1073. PubMed ID: 28871815
[TBL] [Abstract][Full Text] [Related]
19. Functional gene variants of CYP3A4.
Werk AN; Cascorbi I
Clin Pharmacol Ther; 2014 Sep; 96(3):340-8. PubMed ID: 24926778
[TBL] [Abstract][Full Text] [Related]
20. CYP3A activity: towards dose adaptation to the individual.
Hohmann N; Haefeli WE; Mikus G
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):479-97. PubMed ID: 26950050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
